Drug Trial Radar · NCT04675788
Novel Approaches for Minimizing Drug-Induced QT Interval Lengthening
Last checked: Nov 19, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
73
Actual
Start
Sep 2, 2021
Primary completion
Apr 16, 2025
Study completion Apr 16, 2025
Sponsor
- Lead sponsor
- Indiana UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Purdue University; National Heart, Lung, and Blood Institute (NHLBI); Harvard University; Cedars-Sinai Medical Center
- First posted
- Dec 19, 2020
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years, up to 99 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This research will determine if: 1) Oral progesterone attenuates drug-induced QT interval, J-Tpeak and Tpeak-Tend lengthening in postmenopausal women 50 years of age or older, and 2) Transdermal testosterone attenuates drug-induced QT interval, J-Tpeak and Tpeak-Tend lengthening in men 65 years of age or older. This investigation will consist of two concurrent prospective, randomized, double-blind, placebo-controlled crossover-design studies in a) Postmenopausal women, and b) Men 65 years of age or older. Study 1: Each postmenopausal woman will take progesterone or placebo capsules for 1 week. After a 14-day "washout" (no progesterone or placebo) each subject will then take the alternative therapy (progesterone or placebo) for 1 week. After 7 days of each treatment, subjects will present to the clinical research center to receive a small dose of the QT interval-lengthening drug ibutilide, and the effect on the QT, J-Tpeak and Tpeak-Tend intervals during the progesterone and placebo phases will be compared. Study 2: Each man 65 years of age or older will apply transdermal testosterone or transdermal placebo gel for 3 days. After a 7-day "washout" (no testosterone or placebo) each subject will then apply the alternative therapy (testosterone or placebo gel) for 1 week. After 3 days of each treatment, subjects will present to the clinical research center to receive a small dose of the QT interval-lengthening drug ibutilide, and the effect on the QT, J-Tpeak and Tpeak-Tend intervals during the testosterone and placebo phases will be compared.
Conditions
- Long QT Syndrome
- Abnormalities, Drug-Induced
Interventions
ProgesteroneDrug
Subjects will receive oral progesterone 400 mg (two x 200 mg capsules) once daily every evening for 7 days
IbutilideDrug
Ibutilide 0.003 mg/kg administered to all subjects to modestly lengthen the QT interval
TestosteroneDrug
Subjects will apply transdermal testosterone gel once daily every morning for 3 days
PlaceboDrug
Lactose capsules
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pre-ibutilide QT-F and QT-Fram intervalsTime frame: Morning of day 8 (after 7 days of progesterone/placebo)
- Pre-ibutilide QT-F and QT-Fram intervalsTime frame: Morning of day 4 (after 3 days of testosterone/placebo)
- Maximum post-ibutilide QT-F and QT-Fram intervalsTime frame: From initiation of ibutilide infusion and for 8 hours after the end of ibutilide infusion
- Percent change from baseline (pre-ibutilide) in maximum QT-F and QT-Fram intervalsTime frame: From initiation of ibutilide infusion and for 8 hours after the end of ibutilide infusion
- Area under the QT-F and QT-Fram versus time curves during and for 1 hour following ibutilide infusionTime frame: From initiation of ibutilide infusion and for 1 hour after the end of ibutilide infusion
- Area under the QT-F and QT-Fram versus time curves during and for 8 hours following ibutilide infusionTime frame: From initiation of ibutilide infusion and for 8 hours after the end of ibutilide infusion
- Pre-ibutilide heart rate-corrected J-Tpeak (J-Tpeakc) intervalsTime frame: Morning of day 8 (after 7 days of progesterone/placebo)
- Pre-ibutilide heart rate-corrected J-Tpeak (J-Tpeakc) intervalsTime frame: Morning of day 4 (after 3 days of testosterone/placebo)
- Maximum post-ibutilide J-Tpeakc intervalsTime frame: From initiation of ibutilide infusion and for 8 hours after the end of ibutilide infusion
- Percent change from baseline (pre-ibutilide) in maximum J-Tpeakc intervalsTime frame: From initiation of ibutilide infusion and for 8 hours after the end of ibutilide infusion
- Area under the J-Tpeakc versus time curve during and for 1 hour following ibutilide infusionTime frame: From initiation of ibutilide infusion and for 1 hour after the end of ibutilide infusion
- Area under the J-Tpeakc versus time curve during and for 8 hours following ibutilide infusionTime frame: From initiation of ibutilide infusion and for 8 hours after the end of ibutilide infusion
- Pre-ibutilide Tpeak-Tend intervalsTime frame: Morning of day 8 (after 7 days of progesterone/placebo)
- Pre-ibutilide Tpeak-Tend intervalsTime frame: Morning of day 4 (after 3 days of testosterone/placebo)
- Maximum post-ibutilide Tpeak-Tend intervalsTime frame: From initiation of ibutilide infusion and for 8 hours after the end of ibutilide infusion
- Percent change from baseline (pre-ibutilide) maximum Tpeak-Tend intervalsTime frame: From initiation of ibutilide infusion and for 8 hours after the end of ibutilide infusion
- Area under the Tpeak-Tend versus time curves during and for 1 hour following ibutilide infusionTime frame: From initiation of ibutilide infusion and for 1 hour after the end of ibutilide infusion
- Area under the Tpeak-Tend versus time curves during and for 8 hours following ibutilide infusionTime frame: From initiation of ibutilide infusion and for 8 hours after the end of ibutilide infusion
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Indiana Clinical Research Center
Indianapolis, Indiana
Indiana University
Indianapolis, Indiana
Purdue University
Indianapolis, Indiana
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.